An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Description complète

Détails bibliographiques

Auteurs principaux:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2025-07-01
Collection:	EBioMedicine
Sujets:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!